Last reviewed · How we verify
NCT05327140: IBP/AxSpA
Reliability of IBP Criteria & Activity Scores in Patients With AxSpA
trial in Axial Spondyloarthritis in 206 participants. Completed in 25 May 2022.
22 February 2022
Quick facts
| Lead sponsor | Zagazig University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 206 |
| Start date | 20 August 2021 |
| Primary completion | 22 February 2022 |
| Estimated completion | 25 May 2022 |
| Sites | 1 location across Egypt |
Conditions studied
- Axial Spondyloarthritis — all drugs for Axial Spondyloarthritis →
- Inflammatory Back Pain — all drugs for Inflammatory Back Pain →
Sponsor
Zagazig University
Who can join
18 and older, any sex, with Axial Spondyloarthritis or Inflammatory Back Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The current ASAS classification of AxSpA relies either on sacroiliitis on imaging plus one SpA feature (imaging arm) or HLA-B27 antigen plus two SpA features (clinical arm), in a patient with chronic back pain and age at onset of less than 45 years. IBP which is a major symptom of SpA depends more on patient's perception which is not usually accurate. As well, disease activity is measured by ASDAS, BASDAI, and BASFAI which depend more on subjective measures. Assessment of reliability of IBP criteria, ASDAS, BASDAI, and BASFAI in diagnosis and evaluation of activity of AxSpA is essential for better health care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05327140
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Axial Spondyloarthritis
Currently open trials in the same condition.
- NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
- NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
- NCT06888193 — A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® · Phase 1 · recruiting
- NCT07414823 — Walking Football for Axial Spondyloarthritis · NA · active not recruiting
- NCT07148414 — A Study of SPY072 in Rheumatic Disease · Phase 2 · recruiting
Other Zagazig University trials
Trials by the same sponsor.
- NCT07423676 — Comparison Between Two Drugs in Sedation of Upper GI Endoscopy · not yet recruiting
- NCT07418307 — Comparison Between Combined Biceps Femoris Short Head Block and Adductor Canal Block Versus Genicular Nerve Block · NA · not yet recruiting
- NCT07435025 — Surgery for Obstructed Gastric Carcinoma · NA · active not recruiting
- NCT07330375 — Effect of Intravenous Dexmedetomidine and Ketamine on Post-Operative Analgesia · Phase 3 · not yet recruiting
- NCT07309731 — Impact OF Cooled Versus Thermal Radiofrequency Denervation In Management Of Chronic Lumber Facet Joint Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05327140 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zagazig University
- Last refreshed: 25 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05327140.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing